v3.26.1
Stockholders’ Deficit (Tables)
 9 Months Ended
Mar. 31, 2026
Stockholders’ Deficit [Abstract]  
Schedule of Common Stock Issued Upon Completion of the Reverse Recapitalization

The following table presents the number of the Company’s common stock issued upon completion of the Reverse Recapitalization:

 

    Shares of
Common		  
    Stock  
ACAC’s common stock outstanding prior to Reverse Recapitalization     3,971,634  
Less: redemption of ACAC’s common stock     (1,744,663 )
Common stock issued to underwriter     43,125  
Total common stock issued upon completion of the Reverse Recapitalization     2,270,096  
Schedule of Stock Based Compensation Expenses

The following table presents the total stock-based compensation expenses included in each of the respective expense line items for the periods presented: 

 

    For the Three Months Ended     For the Nine Months Ended  
    March 31,     March 31,  
    2026     2025     2026     2025  
    (Unaudited)     (Unaudited)     (Unaudited)     (Unaudited)  
Selling expenses   $ 37,830     $ 28,513     $ 269,628     $ 132,952  
General and administrative expenses     172,599       224,917       517,795       275,912  
Research and development expenses     68,789       73,158       194,914       118,678  
Total stock-based compensation expenses   $ 279,218     $ 326,588     $ 982,337     $ 527,542  
Schedule of Restricted Stock Units Granted

The following table summarizes the activity for all restricted stock units granted for the three and nine months ended March 31, 2026 and 2025:

 

    Shares     Weight average
grant date
fair value		     Total
fair value		     Weighted average  
remaining
contractual
term
(in years)		  
Unvested at June 30, 2025     693,929     $ 7.21     $ 5,001,916       3.36  
Granted     -     $ -       -       -  
Vested     -     $ -       -       -  
Forfeited     (9,574 )   $ 7.30       (69,891 )     -  
Unvested at September 30, 2025     684,355     $ 7.21       4,932,025       3.11  
Granted     -     $ -       -       -  
Vested     (182,214 )   $ 7.30       (1,330,162 )     -  
Forfeited     (31,817 )   $ 7.30       (232,264 )     -  
Unvested at December 31, 2025     470,324     $ 7.16       3,369,599       2.86  
Granted     -     $ -       -       -  
Vested     (42,380 )   $ 6.92       (293,433 )     -  
Forfeited     -     $ -       -       -  
Unvested at March 31, 2026     427,944     $ 7.19     $ 3,076,166       2.61  

 

    Shares     Weight
average
grant date
fair value		     Total fair
value		     Weighted
average  
remaining
contractual
term
(in years)		  
Unvested at July 1, 2024     -     $ -     $ -       -  
Granted     -       -       -       -  
Vested     -       -       -       -  
Forfeited     -       -       -       -  
Unvested at September 30, 2024     -       -       -       -  
Granted     707,860       7.30       5,167,378       4.00  
Vested     -       -       -       -  
Forfeited     -       -       -       -  
Unvested at December 31, 2024     707,860       7.30       5,167,378       3.85  
Granted     19,149       3.97       76,022       4.00  
Vested     -       -       -       -  
Forfeited     -       -       -       -  
Unvested at March 31, 2025     727,009     $ 7.21     $ 5,243,400       3.61  
Schedule of Warrants Activity

The summary of warrants activity is as follows:

 

    Warrants
Outstanding		     Common
Stock
Issuable		     Weighted
Average
Exercise
Price		     Average
Remaining
Contractual
Life		  
June 30, 2025     12,145,917       12,145,917     $ 11.50       4.24  
Granted     -       -     $ -       -  
Forfeited     -       -     $ -       -  
Exercised     -       -     $ -       -  
September 30, 2025     12,145,917       12,145,917     $ 11.50       3.99  
Granted     -       -     $ -       -  
Forfeited     -       -     $ -       -  
Exercised     -       -     $ -       -  
December 31, 2025     12,145,917       12,145,917     $ 11.50       3.74  
Granted     -       -     $ -       -  
Forfeited     -       -     $ -       -  
Exercised     -       -     $ -       -  
March 31, 2026     12,145,917       12,145,917     $ 11.50       3.49  

  

 

    Warrants
Outstanding		     Common
Stock
Issuable		     Weighted
Average
Exercise
Price		     Average
Remaining
Contractual
Life		  
June 30, 2024                   $ -       -  
Granted     12,156,417       12,156,417     $ 11.50       5.00  
Forfeited     -       -     $ -       -  
Exercised     -       -     $ -       -  
September 30, 2024     12,156,417       12,156,417     $ 11.50       4.99  
Granted     -       -     $ -       -  
Forfeited     -       -     $ -       -  
Exercised     (10,500 )     (10,500 )   $ 11.50       -  
December 31, 2024     12,145,917       12,145,917     $ 11.50       4.74  
Granted     -       -     $ -       -  
Forfeited     -       -     $ -       -  
Exercised     -       -     $ -       -  
March 31, 2025     12,145,917       12,145,917     $ 11.50       4.49  

 

The Company accounted for the 12,145,917 Warrants assumed from the merger as equity instruments in accordance with ASC 480, Distinguishing Liabilities from Equity, and ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity.  As of March 31, 2026 and June 30, 2025, the Warrants had no intrinsic value, as the Company’s stock price was below the strike price.